The global prevalence and prevention progress of lung cancer

doi:10.19401/j.cnki.1007-3639.2020.10.001

Welcome to China Oncology,

China Oncology ›› 2020, Vol. 30 ›› Issue (10): 721-725.doi: 10.19401/j.cnki.1007-3639.2020.10.001

• Specialists’ Commentary and Article • Previous Articles Next Articles

The global prevalence and prevention progress of lung cancer

XIAO Jialong, ZHENG Ying

Department of Cancer Prevention Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Online:2020-10-30 Published:2020-11-11
Contact: ZHENG Ying E-mail: zhengying@fudan.edu.cn

Share article

Abstract

Abstract: “World Cancer Report 2020” was published by the International Agency for Research on Cancer (IARC) with the context of China. This article briefly introduced the global and Chinese lung cancer prevalence and survival, and the related research progress on the main risk factors of lung cancer, including genetic susceptibility, major carcinogens, air pollution, past lung diseases, as well as screening and other prevention.

Key words: Lung cancer, Incidence, Risk factor, Screening

XIAO Jialong, ZHENG Ying. The global prevalence and prevention progress of lung cancer[J]. China Oncology, 2020, 30(10): 721-725.

[1]	WANG Zifei, DING Yahui, LI Yan, LUAN Xin, TANG Min. Application of 3D bioprinting in cancer research and tissue engineering [J]. China Oncology, 2024, 34(9): 814-826.
[2]	WANG Manli, CHEN Hui, DUAN Zhi, XU Qimei, LI Zhen. A study on communication mechanism of lung cancer cells in tumor microenvironment mediated by pleckstrin-2/miR-196a signal axis [J]. China Oncology, 2024, 34(7): 628-638.
[3]	TANG Nan, HUANG Huixia, LIU Xiaojian. Integrated single-cell sequencing and transcriptome sequencing to reveal a 9-gene prognostic signature of immune cells in colorectal cancer [J]. China Oncology, 2024, 34(6): 548-560.
[4]	CHEN Hong, CAO Zhiyun. Recent progress in the construction and application of patient-derived pancreatic cancer organoid models [J]. China Oncology, 2024, 34(6): 590-597.
[5]	QIAN Bin, CHEN Haiquan. Important progress in surgical treatment of lung cancer in 2023 [J]. China Oncology, 2024, 34(4): 335-339.
[6]	LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan. Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications [J]. China Oncology, 2024, 34(4): 368-379.
[7]	JIANG Mengqi, HAN Yuchen, FU Xiaolong. Research progress on H-E stained whole slide image analysis by artificial intelligence in lung cancer [J]. China Oncology, 2024, 34(3): 306-315.
[8]	China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee. Expert consensus on population-based BRCA germline mutation screening in China (2024 edition) [J]. China Oncology, 2024, 34(2): 220-238.
[9]	JIANG Yuanyuan, WEI Wenfei, WU Jingya, LI Huawen. Application of organoids in drug screening of gynecological malignant tumors [J]. China Oncology, 2024, 34(11): 1053-1060.
[10]	Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association . Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition) [J]. China Oncology, 2024, 34(1): 13-66.
[11]	WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong. The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer [J]. China Oncology, 2023, 33(9): 844-856.
[12]	ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis [J]. China Oncology, 2023, 33(8): 776-781.
[13]	ZHANG Haoting, ZHENG Jing, FU Mengjiao, ZHOU Jianying. Research progress on thyroid dysfunction induced by immunotherapy for lung cancer [J]. China Oncology, 2023, 33(7): 701-706.
[14]	TANG Duocai, ZHOU Shukui, ZHANG Guiyin, LIU Lei, LIAO Hong. Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor [J]. China Oncology, 2023, 33(5): 478-483.
[15]	WANG Hui, WANG Xia, GAO Yi, XU Jing, YU Xiaojuan, FAN Fangqin, DING Yan, KANG Yu. Current status and influencing factors of gene screening in first-degree relatives of patients with hereditary breast-ovarian cancer syndrome [J]. China Oncology, 2023, 33(5): 499-505.

The global prevalence and prevention progress of lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments